Clinical Trials

82 enrolled

Triple Negative Breast Neoplasms

NCT03412643 2023-03-06

FB-12

64 enrolled

Breast Neoplasms

NCT05580887 2022-10-14

Intestinal Microbiota Impact for Prognosis and Treatment Outcomes in Early Luminal Breast Cancer and Pancreatic Cancer Patients

Unknown

35 enrolled

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms

NCT01547741 2022-04-14

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

1,871 enrolled

Breast Neoplasms

NCT02499367 2022-03-22

TONIC

84 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05088057 2021-10-21

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT04559308 2020-09-22

The Effect of Metformin on Breast Cancer Patients

80 enrolled

Breast Neoplasms

NCT02506777 2019-09-04

MBC1

96 enrolled

Breast Neoplasms

NCT03949634 2019-05-14

Cardiac Safety and Efficacy for Early-stage Breast Cancer Patients Treated With Pegylated Liposomal Doxorubicin（PLD)

272 enrolled

Breast Neoplasms

NCT03925233 2019-04-24

Breast Cancer Treatment Based on Organ-like Culture

Unknown

300 enrolled

Breast Cancer Organoids

NCT03497702 2018-04-13

NeoChAI

114 enrolled

Breast Neoplasms

NCT02953184 2017-12-29

Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy

160 enrolled

Breast Neoplasms

NCT03349177 2017-11-21

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

Phase 2/3 Unknown

200 enrolled

Breast Neoplasms

NCT00408408 2017-09-18

Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery

1,206 enrolled 19 charts

Breast Neoplasms

NCT01176799 2016-06-22

Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor

73 enrolled

Breast Neoplasms

NCT00486668 2016-06-06

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

529 enrolled

Invasive Breast Cancer

NCT02685657 2016-02-22

Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer

164 enrolled

Triple Negative Breast Neoplasms

NCT01784120 2016-02-10

A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer

48 enrolled

Breast Neoplasms

NCT02078388 2014-03-05

Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients

Unknown

500 enrolled

Breast Neoplasms

NCT00012311 2014-01-06

Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Chemotherapy Alone in Treating Women With Stage IV Breast Cancer

Breast Neoplasms

NCT00436709 2014-01-06

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Phase NA Unknown

75 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT00036985 2013-12-19

Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer

Breast Neoplasms

NCT00669773 2013-12-10

Validate Gene Expression and Proteomic Signatures Predictive of Treatment for Response for Breast Cancer Patient

49 enrolled

Breast Neoplasms

NCT00003679 2013-11-06

Combination Chemotherapy in Treating Women With Breast Cancer

350 enrolled

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00533936 2013-08-26

Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer

160 enrolled

Breast Neoplasms

NCT00516425 2013-08-07

Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer

1,000 enrolled

Breast Neoplasms

NCT00629278 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

2,500 enrolled

Breast Neoplasms

NCT01917578 2013-08-06

BCSMANC

4 enrolled

Breast Neoplasms

NCT00538395 2011-12-13

Intensive Sequential Chemotherapy With Adriamycin Taxol and Cytoxan in the Treatment of Locally Advanced Breast Cancer

Phase NA Unknown

100 enrolled

Breast Neoplasms

NCT01415336 2011-08-11

AX Versus AC as Adjuvant Treatment for Node-Negative Breast Cancer

Phase 2/3 Unknown

300 enrolled

Breast Neoplasms

NCT00994968 2010-10-29

Doxorubicin Hydrochloride, Cyclophosphamide, Docetaxel, and S-1 Before Surgery in Treating Women With Stage II or Stage III Breast Cancer

49 enrolled

Breast Neoplasms

NCT00801411 2009-06-17

Cyclophosphamide and Docetaxel or Doxorubicin in Treating Women With Newly Diagnosed Breast Cancer That Can Be Removed by Surgery

318 enrolled

Breast Neoplasms

NCT00294996 2009-03-31

Trial of Myocet in Metastatic Breast Cancer

363 enrolled

Breast Neoplasms

NCT00525642 2007-09-06

Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer

Phase 2/3 Unknown

603 enrolled

Breast Neoplasms

NCT00250874 2005-11-08

Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer

45 enrolled